Description: Abnova (Taiwan) Corporation manufactures and sells various recombinant proteins and antibodies. The company's products portfolio includes SARS-CoV/CoV-2, DNA and RNA, proteins/peptides, DNAxPab, beads/dyes, lysates/slides, antibody pairs/kits, antibody and tissue arrays, in situ hybridization products, systems and automations, GMP and analyte specific reagents, and in vitro diagnostics. It also provides MaxPab, monoclonal, polyclonal, recombinant, conjugate, secondary/tag, IHC/pathology, and circulating rare cell antibodies. In addition, the company offers integrated solutions and services, including gene synthesis and cytogenetics; peptide services, protein expression, and conjugations; antibody production; and assay development services. Abnova (Taiwan) Corporation is headquartered in Taipei, Taiwan.
Home Page: www.abnova.com
No. 108, Jhouzih Street
Taipei,
114
Taiwan
Phone:
886 2 8751 1888
Exchange: TW
Country: TW
Currency: New Taiwan Dollar (NT$)
GIC Sector: | Health Care |
---|---|
GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
GIC Industry: | Life Sciences Tools & Services |
GIC Sub-Industry: | Life Sciences Tools & Services |
Forward PE: | 0 |
---|---|
Trailing PE: | 37.451 |
Price-to-Book MRQ: | 1.9802 |
Price-to-Sales TTM: | 5.8565 |
IPO Date: | |
Fiscal Year End: | December |
Full Time Employees: | 0 |